Nirsevimab Greatly Reduced Severe RSV in Infants
For infants in their first RSV season, the monoclonal antibody Nirsevimab (Beyfortus) was 80% effective against RSV-related ICU admission and...
For infants in their first RSV season, the monoclonal antibody Nirsevimab (Beyfortus) was 80% effective against RSV-related ICU admission and...
If you’re looking to reduce your chances of developing lung disease, say experts at UC San Francisco, then it may...